EP1102788A4 - Prevention and treatment of viral disease - Google Patents

Prevention and treatment of viral disease

Info

Publication number
EP1102788A4
EP1102788A4 EP99945011A EP99945011A EP1102788A4 EP 1102788 A4 EP1102788 A4 EP 1102788A4 EP 99945011 A EP99945011 A EP 99945011A EP 99945011 A EP99945011 A EP 99945011A EP 1102788 A4 EP1102788 A4 EP 1102788A4
Authority
EP
European Patent Office
Prior art keywords
prevention
treatment
viral disease
viral
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99945011A
Other languages
German (de)
French (fr)
Other versions
EP1102788A2 (en
Inventor
Jack H Nunberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Montana
Original Assignee
University of Montana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Montana filed Critical University of Montana
Publication of EP1102788A2 publication Critical patent/EP1102788A2/en
Publication of EP1102788A4 publication Critical patent/EP1102788A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99945011A 1998-08-03 1999-08-03 Prevention and treatment of viral disease Withdrawn EP1102788A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9510598P 1998-08-03 1998-08-03
US95105P 1998-08-03
US14180699P 1999-06-29 1999-06-29
US141806P 1999-06-29
PCT/US1999/017487 WO2000008043A2 (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease

Publications (2)

Publication Number Publication Date
EP1102788A2 EP1102788A2 (en) 2001-05-30
EP1102788A4 true EP1102788A4 (en) 2002-08-28

Family

ID=26789760

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99945011A Withdrawn EP1102788A4 (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease

Country Status (9)

Country Link
EP (1) EP1102788A4 (en)
JP (1) JP2002522448A (en)
KR (1) KR20010085326A (en)
CN (1) CN1321165A (en)
AU (1) AU5771599A (en)
BR (1) BR9912732A (en)
CA (1) CA2338983A1 (en)
IL (1) IL141211A0 (en)
WO (1) WO2000008043A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523721A (en) 1998-12-31 2003-08-12 カイロン コーポレイション Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof
FR2789590B1 (en) * 1999-02-15 2003-01-17 Inst Rech Developpement Ird IMMUNOGENIC COMPOSITIONS FOR USE AS VACCINES
EP1130089A1 (en) * 2000-02-17 2001-09-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Composition comprising membrane virus subviral target and fusion particles and vaccine comprising said composition
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
MXPA03002480A (en) 2000-09-22 2004-05-24 Univ Duke Immunogen comprising ligand bound hiv envelpe protein.
ES2260416T3 (en) * 2001-01-05 2006-11-01 Sanofi Pasteur POLYPEPTIDE INDUCING ANTIBODIES THAT NEUTRALIZE HIV.
FR2819256B1 (en) * 2001-01-05 2004-04-30 Aventis Pasteur POLYPEPTIDE INDUCING HIV NEUTRALIZING ANTIBODIES
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
WO1993005147A1 (en) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defective interfering hiv particles with chimeric cd4-env

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LACASSE ET AL.: "Fusion-competent vaccines: Broad neutralization of primary isolates of HIV", SCIENCE, vol. 283, 15 January 1999 (1999-01-15), pages 357 - 362, XP002120812 *
NUNBERG, J.: "Retraction", SCIENCE, vol. 296, 10 May 2002 (2002-05-10), pages 1025 *
THALI ET AL.: "Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding", J. VIROLOGY, vol. 67, no. 7, July 1993 (1993-07-01), pages 3978 - 3988, XP000579277 *
WHITE-SCHARF: "Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization", VIROLOGY, vol. 192, 1993, pages 197 - 206, XP002203539 *
WYATT & SODROSKI: "The HIV-1 envelope glyycoproteins: fusogens, antigens and immunogens", SCIENCE, vol. 280, 19 June 1998 (1998-06-19), pages 1884 - 1888, XP002203540 *

Also Published As

Publication number Publication date
AU5771599A (en) 2000-02-28
JP2002522448A (en) 2002-07-23
WO2000008043A3 (en) 2000-05-11
KR20010085326A (en) 2001-09-07
EP1102788A2 (en) 2001-05-30
CN1321165A (en) 2001-11-07
CA2338983A1 (en) 2000-02-17
BR9912732A (en) 2001-11-27
WO2000008043A2 (en) 2000-02-17
IL141211A0 (en) 2002-02-10
WO2000008043A9 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
SG111083A1 (en) Prevention and treatment of amyloidogenic disease
GB2368794B (en) Prevention and treatment of amyloidogenic disease
HUP0201205A2 (en) Prevention and treatment of amyloidogenic disease
IL132003A0 (en) Antimicrobial prevention and treatment of human immundeficiency virus and other infectious diseases
IL129352A0 (en) Benzimidazole-2- carbamates for the treatment of viral infections and cancer
EP1109580A4 (en) Methods for treating or preventing viral infections and associated diseases
EP1115286A4 (en) Methods for treating or preventing viral infections and associated diseases
HK1043019B (en) Compositions and methods for prevention and treatment of protozoal disease
DE69836209D1 (en) PREVENTION AND TREATMENT OF HEPATOCELLULAR CANCER
IL138692A0 (en) Treatment and prevention of vascular disease
IL141211A0 (en) Prevention and treatment of viral disease
EP1173189A4 (en) Asialocytokines and treatment of liver disease
EP1107778A4 (en) Treatment of disease states
EP0833641A4 (en) Treatment and prevention of prostatic disease
GB9516572D0 (en) Prevention and/or treatment of disease
GB0016197D0 (en) Treatment and prevention of disease
GB0030865D0 (en) Treatment and prevention of disease
GB0030866D0 (en) Treatment and prevention of disease
ZA9810932B (en) Prevention of and treatment of amyloidogenic disease.
IL141880A0 (en) Treatment of depression
AU2003203740A1 (en) Prevention and treatment of amyloidogenic disease
GB9726745D0 (en) Treatment of medical conditions
GB9710054D0 (en) Treatment of diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010302

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07H 21/04 A, 7A 61K 48/00 B, 7A 61K 39/395 B, 7C 12N 1/20 B, 7A 61K 39/21 B, 7C 07K 14/16 B, 7C 12N 15/62 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020711

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030302